JNJ · News · 20260912N
DePuy Synthes Divestiture
JOHNSON & JOHNSON · 2026-09-12 · Importance 58 · Surprise 42 · In source text
Johnson & Johnson is reportedly in discussions to sell its DePuy Synthes hips-and-knees orthopedics business to Apollo Global Management. The potential transaction is valued at approximately $20 billion, materially exceeding the company’s $759 million revenue-materiality threshold. The divestiture would support J&J’s strategy of focusing on higher-growth areas, but discussions remain ongoing, a deal is not guaranteed, and other bidders could emerge.
Key facts
- Johnson & Johnson is reportedly in discussions to sell its DePuy Synthes hips-and-knees orthopedics business to private-equity firm Apollo Global Management for approximately $20 billion. source
- Continuum Advisory LLC cut its holdings in shares of Johnson and Johnson (NYSE: JNJ) by 47.4% during the undefined quarter; the firm owned 4,515 shares of the company's stock after selling 4,074 shares during the period. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| cash | positive | contingent | +1.5% | Johnson & Johnson is reportedly in discussions to sell its DePuy Synthes hips-and-knees orthopedics business to private-equity firm Apollo… |
| revenue | negative | contingent | — | Johnson & Johnson is reportedly in discussions to sell its DePuy Synthes hips-and-knees orthopedics business to private-equity firm Apollo… |